Core Viewpoint - Zoetis, Inc. is expected to report its first-quarter 2025 earnings on May 6, 2025, with revenue estimates at $2.19 billion and earnings at $1.40 per share [1]. Group 1: Revenue Sources - The company generates most of its revenues from a diversified portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional revenues from non-pharmaceutical categories like nutritional products and precision animal health services [2]. - In the United States segment, revenues are projected to increase to $1.19 billion, driven by rising sales of companion animal products, with model estimates at $1.17 billion [3]. - The International segment is also expected to see revenue growth, estimated at $0.99 billion, with model estimates at $1.01 billion, primarily due to higher sales of companion animal products [4]. Group 2: Product Performance - Sales of companion animal products, particularly monoclonal antibodies for osteoarthritis pain (Librela for dogs and Solensia for cats), and the flea, tick, and heartworm combination product Simparica Trio, are anticipated to drive revenue growth in both segments [5]. - The FDA recently approved a new indication for Simparica Trio, enhancing its market position as the only canine combination parasiticide indicated to prevent flea tapeworm infections, which is expected to boost future sales [7]. - Livestock product sales in the U.S. are expected to decline due to the divestiture of certain product lines, while international livestock sales are projected to rise, driven by price increases in cattle and poultry portfolios [8]. Group 3: Earnings Surprise History - Zoetis has a strong earnings surprise history, surpassing estimates in the last four quarters with an average surprise of 4.53%, including a 2.19% surprise in the last reported quarter [10]. - The current Earnings ESP for Zoetis is -1.15%, indicating that the most accurate estimate of $1.38 per share is lower than the consensus estimate of $1.40 per share [12].

Core Viewpoint - Columbia Sportswear Company (COLM) is expected to report a decline in both revenues and earnings for the first quarter of 2025, with revenues estimated at $761.9 million, reflecting a 1.1% decrease year-over-year [1]. Revenue Expectations - The Zacks Consensus Estimate for first-quarter revenues is $761.9 million, indicating a 1.1% decrease from the previous year, aligning with the company's guidance of a 1-3% decline, projecting net sales between $749 million and $764 million [1][2]. - The decline in revenues is attributed to the absence of last year's unusually cold winter, which had temporarily boosted demand, and a return to normalized shipping patterns after accelerated shipments in the previous year [2]. Earnings Projections - The consensus estimate for first-quarter earnings per share is stable at 69 cents, representing a 2.8% decline from the year-ago period, with management guiding earnings between 62 cents and 70 cents per share [2]. - Columbia Sportswear has delivered an average earnings surprise of 36.7% over the trailing four quarters [2]. Market Conditions - The company is facing a challenging U.S. market characterized by softened consumer demand, although it has seen stronger performance internationally, particularly in China and the EMEA region [3]. Operating Margin Insights - The projected operating margin for the first quarter is between 5.4% and 6%, with a midpoint of 5.7%, which is a decrease of 10 basis points from the same quarter last year [4]. Strategic Initiatives - Columbia Sportswear's product innovation, ACCELERATE Growth Strategy, and cost-saving initiatives are expected to provide some support against the anticipated declines, with efforts to expand premium product lines and enhance marketing investments [5]. Earnings Prediction Model - The Zacks model does not predict an earnings beat for Columbia Sportswear this quarter, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [6].

Alamos Gold (AGI) is expected to report an improvement in its bottom line when it reports first-quarter 2025 results on April 30, 2025, after market close. The Zacks Consensus Estimate for Alamos Gold’s earnings has moved down 13.6% over the past 60 days to 19 cents per share. The figure indicates 46% growth from the year-ago quarter. Image Source: Zacks Investment ResearchAGI’s Earnings Surprise HistoryIn the trailing four quarters, Alamos Gold’s earnings matched the Zacks Consensus Estimate in one quarter ...

Core Viewpoint - Eli Lilly and Company is set to report its first-quarter earnings on May 1, with sales and earnings estimates at $12.62 billion and $3.52 per share respectively, while earnings estimates for 2025 have seen a decline from $23.53 to $22.43 per share over the past month [1][4]. Earnings Performance - The company has exceeded earnings expectations in three of the last four quarters, with an average earnings surprise of 8.47% [2][3]. - The last reported quarter showed an earnings surprise of 5.77% [2]. Earnings Estimates and Trends - Current earnings estimates for Q1, Q2, 2025, and 2026 are $3.52, $5.58, $22.43, and $31.15 respectively, with a notable decline in Q1 estimates from $4.64 to $3.52 over the past 30 days, reflecting a -22.30% revision [1][4]. Factors Influencing Upcoming Results - Top-line growth in Q1 is expected to be driven by demand for FDA-approved tirzepatide medicines, specifically diabetes drug Mounjaro and weight loss medicine Zepbound [5]. - Sales of Mounjaro and Zepbound were below expectations in the latter half of 2024, attributed to slower growth and unfavorable channel dynamics [5][6]. - The FDA's approval of Zepbound for moderate-to-severe obstructive sleep apnea is anticipated to contribute positively to sales [7]. Sales Estimates for Key Products - The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion respectively, while internal estimates are $3.82 billion and $2.19 billion [8]. - Sales estimates for other drugs include Trulicity at $1.11 billion, Taltz at $663 million, Verzenio at $1.25 billion, Jardiance at $675 million, Olumiant at $228 million, and Emgality at $220 million [10]. Competitive Landscape - Lilly faces competition in the diabetes and obesity market, particularly from Novo Nordisk's Wegovy, with several companies developing GLP-1-based candidates that could threaten market dominance [22][23]. - Despite competition, Lilly is investing in obesity treatments and has new molecules in clinical development, including a promising oral GLP-1 agonist [24]. Stock Performance and Valuation - Lilly's stock has increased by 14.8% this year, outperforming the industry average of 1.5% [13]. - The stock is currently trading at a premium compared to the industry [16]. Investment Outlook - Despite challenges, Lilly is viewed as a strong investment due to its robust growth prospects and position as a leading drugmaker [25].

Core Viewpoint - Spotify Technology S.A. is expected to report strong earnings growth in Q1 2025, with earnings per share estimated at $2.32, reflecting a 121% year-over-year increase, and revenues projected at $4.5 billion, indicating a 13.3% growth compared to the previous year [1]. Earnings Estimates - The Zacks Consensus Estimate for Q1 earnings has seen two upward revisions and one downward revision in the past 30 days, with a 1.3% increase in the 2024 earnings estimate during the same period [2]. - The current earnings estimates for Q1, Q2, E1, and F2 are $2.32, $2.44, $10.55, and $13.56 respectively, showing a positive trend in revisions over the last 60 days [3]. Earnings Surprise History - Spotify has a notable earnings surprise history, surpassing the Zacks Consensus Estimate in two of the last four quarters, with an average positive surprise of 22% [4]. Earnings Prediction Model - The current Earnings ESP for Spotify is -8.61%, and it holds a Zacks Rank of 3 (Hold), indicating that the model does not predict a definitive earnings beat this time [5][6]. Subscriber Growth - The growth in subscribers and monthly active users (MAU) is expected to positively impact both revenue and earnings, with total MAUs estimated at 678.3 million (10.3% year-over-year growth), ad-supported MAUs at 426.4 million (10% growth), and premium subscribers at 265.41 million (11% growth) [8]. Stock Performance - Spotify's stock has experienced significant price increases, rallying 35% year-to-date, 58% over the past six months, and 109% in the past year, indicating a strong upward trend [9]. Investment Considerations - The company's strong performance metrics are attributed to price hikes, a loyal consumer base, and cost reductions, which have contributed to growth in both top and bottom lines [10]. - The expectation is for another robust quarterly performance driven by subscriber gains and increases in average revenue per user (ARPU), which will enhance the company's financial position [11]. Long-term Outlook - While current growth prospects for Spotify appear strong, there may be a potential correction in the stock price, suggesting that investors might consider waiting for a more opportune moment to invest [12]. - The long-term growth potential of the company remains strong, making it a stock to monitor for future investment opportunities [14].

Core Viewpoint - United Parcel Service (UPS) is expected to report a decline in both earnings and revenues for the first quarter of 2025, with earnings estimated at $1.42 per share, a 0.7% decrease from the previous year, and revenues projected at $21.06 billion, indicating a 3% decline from the same quarter last year [1][2]. Earnings and Revenue Estimates - The Zacks Consensus Estimate for UPS's earnings is $1.42 per share, reflecting a downward revision of seven cents over the past 60 days [1]. - Revenue estimates stand at $21.06 billion, which is a 3% decline compared to the year-ago quarter [2]. Earnings Surprise History - UPS has a history of earnings surprises, with an average surprise of 3.43% across the last four quarters [3]. Earnings Prediction Model - The current Earnings ESP for UPS is -4.08%, indicating a lower likelihood of an earnings beat this quarter [5][6]. - UPS holds a Zacks Rank of 4 (Sell), suggesting a bearish outlook [6]. Factors Influencing Q1 Results - Geopolitical uncertainties and high inflation are expected to negatively impact shipping volumes [7]. - Labor costs are anticipated to be high, while low fuel costs may provide some relief, with a projected 5.1% decrease in fuel expenses compared to Q1 2024 [8]. Stock Performance - UPS stock has declined by 32.9% over the past year, underperforming its industry, which saw a 29.7% decline, while the S&P 500 rose by 7% [10]. Valuation Metrics - UPS is trading at a forward sales multiple of 0.96, which is higher than its industry peers, indicating a stretched valuation [13]. Investment Thesis - A decline in shipping demand is expected, with average daily volumes projected to decrease by 8.5% in 2025 compared to 2024 [16]. - Recent easing signals in the U.S.-China trade tensions may provide some optimism, but concerns over dividend sustainability amid demand weakness remain [18]. Long-term Outlook - Despite near-term challenges, UPS's strong brand and network position it as a compelling long-term investment in the transportation sector [19].

Core Viewpoint - American Water Works (AWK) is expected to report its first-quarter 2025 results on April 30, with a prior earnings surprise of 7.96% in the last quarter [1] Group 1: Factors Impacting Q1 Performance - The first-quarter earnings are anticipated to benefit from infrastructure improvements due to capital investments and efficient cost management strategies [2] - In 2024, AWK completed 13 acquisitions, adding 69,500 new customers, which is expected to create fresh demand and boost quarterly revenues [2] - Nearly 100% of AWK's net income is generated from regulated operations, with new rates effective in the first quarter likely contributing positively to performance [3] Group 2: Q1 Expectations - The Zacks Consensus Estimate for earnings is $1.04 per share, reflecting a year-over-year increase of 9.5% [4] - The Zacks Consensus Estimate for revenues is $1.03 billion, indicating a 1.8% increase from the previous year [4] Group 3: Earnings Prediction - The current model does not predict an earnings beat for AWK, with an Earnings ESP of 0.00% [5] - AWK holds a Zacks Rank of 2 (Buy) [6] Group 4: Comparable Stocks - Middlesex Water Company (MSEX) is expected to report an earnings beat with an Earnings ESP of +9.09% and a Zacks Rank 1 [7] - Evergy (EVRG) is also likely to report an earnings beat with an Earnings ESP of +5.7% and a Zacks Rank 3 [8] - Essential Utilities (WTRG) is projected to have an earnings beat with an Earnings ESP of +2.08% and a Zacks Rank 3 [10]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Patria Investments, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - The earnings report is expected on May 2, 2025, with a consensus EPS estimate of $0.25, reflecting a +19.1% change year-over-year, and revenues projected at $81.42 million, up 34.4% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Patria Investments is lower than the consensus estimate, resulting in an Earnings ESP of -8%, indicating a bearish sentiment among analysts [10][11]. Historical Performance - In the last reported quarter, Patria Investments exceeded the expected EPS of $0.37 by delivering $0.58, resulting in a surprise of +56.76%. However, the company has only beaten consensus EPS estimates once in the last four quarters [12][13]. Conclusion - Given the current Earnings ESP and Zacks Rank of 4, Patria Investments does not appear to be a strong candidate for an earnings beat, suggesting that investors should consider additional factors before making investment decisions [16].

Company Overview - Amneal Pharmaceuticals (AMRX) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.15, reflecting a change of +7.1% [3] - Revenues are anticipated to reach $714.78 million, representing an 8.4% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised 3.23% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The company has an Earnings ESP of +2.27%, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Amneal's actual earnings were $0.12 per share, which was a -20% surprise compared to the expected $0.15 [12] - Over the last four quarters, Amneal has beaten consensus EPS estimates three times [13] Market Sentiment - The upcoming earnings report is set to be released on May 2, and the stock may move higher if the results exceed expectations [2] - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a favorable outlook for Amneal's earnings performance [11]

Core Viewpoint - Atmus Filtration Technologies (ATMU) is anticipated to report a year-over-year decline in earnings and revenues for the quarter ended March 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for May 2, 2025, with a consensus estimate of $0.59 per share, reflecting a -1.7% change year-over-year. Revenues are projected to be $420.68 million, down 1.4% from the previous year [3][2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.02%, indicating a collective reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Atmus Filtration is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.09%. This suggests a bearish sentiment among analysts regarding the company's earnings prospects [10][11]. Historical Performance - In the last reported quarter, Atmus Filtration exceeded the expected earnings of $0.53 per share by delivering $0.58, resulting in a surprise of +9.43%. The company has beaten consensus EPS estimates in the last four quarters [12][13]. Investment Considerations - Despite the potential for an earnings beat, Atmus Filtration does not currently appear to be a compelling candidate for such an outcome, especially given its Zacks Rank of 4, which complicates predictions of beating the consensus EPS estimate [16][11].